CXCL8 and cystic fibrosis: The dual therapy ivacaftor/lumacaftor increased the tumor suppressor and anti-inflammatory phosphatase and tensin homolog (PTEN) expression on the plasma membrane of CF monocytes [144], reduced the secretion of pro-inflammatory cytokines (IL-6, IL-8, TNF-α, IFNγ, GM-CSF) by monocyte-derived macrophages in response to P. aeruginosa [133], decreased B. cenocepacia phagocytosis [129], and reduced Aspergillus fumigatus-induced ROS [134].